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ARTICLE OPEN
Accuracy of Vitalograph lung monitor as a screening test for
COPD in primary care
A. P. Dickens 1*, D. A. Fitzmaurice2, P. Adab1*, A. Sitch1, R. D. Riley3, A. Enocson1 and R. E. Jordan1
Microspirometry may be useful as the second stage of a screening pathway among patients reporting respiratory symptoms. We
assessed sensitivity and speciﬁcity of the Vitalograph® lung monitor compared with post-bronchodilator conﬁrmatory spirometry
(ndd Easy on-PC) among primary care chronic obstructive pulmonary disease (COPD) patients within the Birmingham COPD cohort.
We report a case–control analysis within 71 general practices in the UK. Eligible patients were aged ≥40 years who were either on a
clinical COPD register or reported chronic respiratory symptoms on a questionnaire. Participants performed pre- and post-
bronchodilator microspirometry, prior to conﬁrmatory spirometry. Out of the 544 participants, COPD was conﬁrmed in 337
according to post-bronchodilator conﬁrmatory spirometry. Pre-bronchodilator, using the LLN as a cut-point, the lung monitor had a
sensitivity of 50.5% (95% CI 45.0%, 55.9%) and a speciﬁcity of 99.0% (95% CI 96.6%, 99.9%) in our sample. Using a ﬁxed ratio of
FEV1/FEV6 < 0.7 to deﬁne obstruction in the lung monitor, sensitivity increased (58.8%; 95% CI 53.0, 63.8) while speciﬁcity was
virtually identical (98.6%; 95% CI 95.8, 99.7). Within our sample, the optimal cut-point for the lung monitor was FEV1/FEV6 < 0.78,
with sensitivity of 82.8% (95% CI 78.3%, 86.7%) and speciﬁcity of 85.0% (95% CI 79.4%, 89.6%). Test performance of the lung
monitor was unaffected by bronchodilation. The lung monitor could be used in primary care without a bronchodilator using a
simple ratio of FEV1/FEV6 as part of a screening pathway for COPD among patients reporting respiratory symptoms.
npj Primary Care Respiratory Medicine            (2020) 30:2 ; https://doi.org/10.1038/s41533-019-0158-2
INTRODUCTION
Chronic obstructive pulmonary disease (COPD) is one of the most
common long-term respiratory conditions with rising burden and
mortality worldwide.1–3 It is characterised by increasing breath-
lessness and decline in lung function, punctuated by episodes of
acute exacerbations that often lead to hospital admission and
result in poor prognosis and gradual deterioration of quality of
life.4 Annual healthcare and societal costs of COPD in Europe are
estimated to be €48.4 billion.5 Despite the high burden of disease,
the large majority of patients with COPD remain undiagnosed6
while experiencing signiﬁcant morbidity,7 resulting in calls to
improve early diagnosis.8,9 Early diagnosis could focus smoking
cessation support and allow prescription of treatments that have
been shown to reduce risk of exacerbation in those with COPD,
thus has the potential to slow disease progression.
Screening programmes are not yet recommended, partly
because of lack of evidence of the long-term beneﬁts,10,11 a view
which is upheld in the most recent UK National Screening
Committee report.12 However, there are also uncertainties around
the performance of available screening tests, including symptom
or risk assessment questionnaires and lung function-based
measures, alone or in combination.12,13 A recent study compared
different screening strategies among current smokers, against
post-bronchodilator spirometry. This concluded that microspiro-
metry or peak ﬂow meters had the best performance, but
interpretation was limited by a small sample size and low-quality
spirometry data.14 Microspirometers are small relatively inexpen-
sive handheld devices that measure forced expiratory volume in
1 s (FEV1) and in 6 s (FEV6). While this is not a substitute for
conﬁrmatory spirometry, which is more time consuming and
measures FEV1 and forced vital capacity (FVC), usually after
bronchodilation, the FEV1/FEV6 ratio could be used as a pragmatic
initial screening test to identify patients requiring conﬁrmatory
spirometry. Microspirometry can be undertaken in ofﬁce settings
and requires less time and patient effort.15–18
Over the past decade, several studies have explored the
accuracy of microspirometers in detecting airﬂow obstruc-
tion.14,19–27 However, none of the studies considered the use of
microspirometers as the second stage of a screening pathway.
Microspirometry as a screening tool is usually performed without
bronchodilation, as this contributes to time savings and avoids the
need for Salbutamol. However, it remains uncertain how micro-
spirometry performance differs when conducted pre- and post-
bronchodilator. Finally, there is little consensus regarding the
optimal FEV1/FEV6 cut-point for referral to conﬁrmatory spirome-
try, with recent studies suggesting ratios of <0.73,22 <0.7521 and
<0.78.19
To address the current evidence gaps, we conducted a study in
primary care patients with existing respiratory symptoms, includ-
ing those pre-screened in our linked trial. We aimed to assess the
test performance of a microspirometer (Vitalograph Lung monitor)
against conﬁrmatory post-bronchodilator spirometry (ndd Easy
on-PC) and explore the effect of using pre- or post-bronchodilator
microspirometer data, the impact of using different airﬂow
obstruction criteria and optimal cut-points.
RESULTS
Follow-up assessments were booked for 1633 participants. Out of
the 1500 participants who attended the assessment, 551 took part
in the case–control study. Lung monitor and spirometry test data
were available for a total of 544 participants (Fig. 1).
Of those, 349 (64.2%) were male, the mean age was 69.6 (9.1)
years, 517 (96.3%) were White British, 382 (74.3%) were
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overweight/obese and 472 (88.1%) had a positive smoking history.
Similar proportions of participants reported Medical Research
Council (MRC) Dyspnoea scores of 1–2 and 3–5, one ﬁfth (19.7%)
had CAT scores representing high impact on daily life and over
half the sample (57.3%) were retired (Table 1).
A total of 337 (62.0%) participants had airﬂow obstruction
according to the reference test, with over three quarters (n= 264,
78.3%) representing GOLD stage I and II i.e. mild/moderate COPD
(Table 1). In comparison with controls, the cases were slightly
older (70.4 vs 68.2 years), more likely to be male (68.3% vs 57.5%),
a higher proportion had a positive smoking history (90.4%
vs 84.3%) and MRC Dyspnoea scores of 3–5 (54.5% vs 40.1%)
(Table 1).
Nearly half of the participants (45.5%) reported exacerbations in
the past 12 months and 37 (6.8%) reported a respiratory
hospitalisation in the past 2 years (Table 1). Cases reported
approximately twice as many exacerbations as controls (54.2% vs
31.4%) in the past 12 months.
Screening accuracy of the pre-bronchodilator lung monitor
Using lower limit of normal (LLN; i.e. the lower 5th percentile) as
the cut-off for a positive result, the pre-bronchodilator lung
monitor had sensitivity of 50.5% (95% conﬁdence interval (CI) 45.0,
55.9) and speciﬁcity of 99.0% (95% CI 96.6, 99.9) (Table 2). The
positive predictive value of the lung monitor was estimated to be
76.9% (95% CI 55.7, 89.8) for a population prevalence of 6%,
dropping to 61.8% (95% CI 37.8, 81.1) for a population prevalence
of 3% and rising to 85.3% (95% CI 68.6, 93.9) for a population
prevalence of 10%.
FEV1 measurements from both devices were highly correlated
(r= 0.97; p < 0.001), with the Bland–Altman plot demonstrating
good agreement (Supplementary Fig. 1). Comparison of FEV6 from
both devices again revealed high correlation (r= 0.95; p < 0.001),
though agreement was lower, indicating that the lung monitor
systematically underestimated FEV6 values by −0.37 litres (Sup-
plementary Fig. 2).
The lung monitor had high discriminatory accuracy (C= 0.90;
95% CI 0.88, 0.93) between cases and controls according to
conﬁrmatory spirometry FEV1/FVC < LLN (Supplementary Fig. 3).
Screening accuracy of the post-bronchodilator lung monitor
Using post-bronchodilator data for the lung monitor, the
sensitivity was 46.6% (95% CI 41.2%, 52.1%) and speciﬁcity was
97.1% (95% CI 93.8%, 98.9%) for detecting airﬂow obstruction
(Table 3). The positive predictive value of the lung monitor was
estimated to be 50.6% (95% CI 42.6, 58.6) for a population
prevalence of 6%.
Comparison of pre- and post-bronchodilator lung monitor test
accuracy revealed a borderline signiﬁcant difference favouring
pre-bronchodilator of 3.9% in sensitivity (7.8%, −0.05%); p= 0.04,
but no statistically signiﬁcant evidence of a difference in speciﬁcity
(1.9% (−0.9%, 4.7%)); p= 0.10.
Lung monitor and conﬁrmatory spirometry tests were also
highly correlated for post-bronchodilator FEV1 (r= 0.97; p < 0.001),
with the Bland–Altman plot again demonstrating good agreement
(Supplementary Fig. 4). Comparison of post-bronchodilator FEV6
again revealed high correlation (r= 0.97; p < 0.001), though
agreement was lower, indicating that the lung monitor
Follow-up assessments
booked
(n=1633)
Follow-up assessments
attended
(n=1500)
Declined involvement in
case-control study
(n=943)
Consented to case-
control study
(n=557)
Completed Cohort
assessment + additional
tests
(n=551)
Completed standard
Cohort assessment
Data available for lung
monitor & spirometry tests
(n=544)
Excluded (n=6)
Contraindicated for spirometry (n=6)
Excluded (n=133)
Did not attend (n=86)
Cancelled (n=40)
Withdrew from study (n=7)
Excluded (n=7)
Salbutamol not given (n=3)
Post-BD lung monitor not done (n=4)
Fig. 1 Flow of the participants.
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Table 1. Description of analysis sample, stratiﬁed by cases and controls.
Analysis sample (n= 544) Cases; <LLN (n= 337) Controls; ≥LLN (n= 207)
Demographic and lifestyle information
Sex; n (%) male 349/544 (64.2) 230/337 (68.3) 119/207 (57.5)
Age, mean (SD) 69.6 (9.1) 70.4 (7.9) 68.2 (10.6)
Ethnicity; n (%)
White British 517/537 (96.3) 322/332 (97.0) 195/205 (95.1)
Other 20/537 (3.7) 10/332 (3.0) 10/205 (4.9)
Weight; n (%)
Underweight (BMI <18.5) 9/514 (1.8) 7/318 (2.2) 2/196 (1.0)
Healthy (≥18.5 and <25) 123/514 (23.9) 85/318 (26.7) 38/196 (19.4)
Overweight (≥25 and <30) 194/514 (37.7) 118/318 (37.1) 76/196 (38.8)
Obese (≥30) 188/514 (36.6) 108/318 (34.0) 80/196 (40.8)
BMI, mean (SD) n= 514 28.6 (5.4) 28.1 (5.4) 29.4 (5.4)
Smoking status; n (%)
Current smoker 111/536 (20.7) 79/332 (23.8) 32/204 (15.7)
Ex-smoker 361/536 (67.4) 221/332 (66.6) 140/204 (68.6)
Never smoker 64/536 (11.9) 32/332 (9.6) 32/204 (15.7)
Employment status; n (%)
Employed 88/534 (16.5) 45/334 (13.5) 43/200 (21.5)
Unemployed 140/534 (26.2) 94/334 (28.4) 46/200 (23.0)
Retired 306/534 (57.3) 195/334 (58.4) 111/200 (55.5)
Airﬂow obstruction
GOLD stage if <LLN
1 (FEV1 ≥80% pred) 87/337 (25.8) 87/337 (25.8) n/a
2 (50–79%) 177/337 (52.5) 177/337 (52.5) n/a
3 (30–49%) 59/325 (18.1) 61/337 (18.1) n/a
4 (<30%) 12/325 (3.6) 12/337 (3.6) n/a
Self-reported health and healthcare usage
MRC; n (%)
1–2 219/427 (51.3) 116/255 (45.5) 103/172 (59.9)
3–5 208/427 (48.7) 139/255 (54.5) 69/172 (40.1)
CAT impact level; n (%)
Low (0–9) 180/406 (44.3) 100/245 (40.8) 80/161 (49.7)
Medium (10–20) 146/406 (36.0) 93/245 (38.0) 53/161 (32.9)
High (21–30) 69/406 (17.0) 47/245 (19.2) 22/161 (13.7)
Very high (31–40) 11/406 (2.7) 5/245 (2.0) 6/161 (3.7)
Asthma; n (%) yes 198/538 (36.8) 129/334 (38.6) 69/204 (33.8)
CVDa; n (%) yes 159/538 (29.6) 94/334 (28.1) 65/204 (31.9)
Other comorbiditiesb; n (%) ≥1 302/540 (55.9) 184/336 (54.8) 111/204 (57.8)
Exacerbations in last 12m; n (%) yes 247/543 (45.5) 182/336 (54.2) 65/207 (31.4)
Respiratory hospitalisation in last 2 years; n (%) yes 37/544 (6.8) 27/337 (8.0) 10/207 (4.8)
LLN= below the 5th percentile of the predicted FEV1/FVC ratio using the NHANES III equations
aCVD was deﬁned as self-reported coronary heart disease, heart failure or other heart condition
bOther comorbidities were deﬁned as self-reported clinician diagnosis of diabetes, osteoporosis, depression, fracture
Table 2. Pre-BD lung monitor (FEV1/FEV6 < LLN) against post-BD
conﬁrmatory spirometry (FEV1/FVC < LLN).
Spirometry +ve Spirometry −ve
Lung monitor +ve 170 (50.5%) 2 (1.0%) 172
Lung monitor −ve 167 (49.6%) 205 (99.0%) 372
337 207 544
Table 3. Post-BD lung monitor (FEV1/FEV6 < LLN) against post-BD
conﬁrmatory spirometry (FEV1/FVC < LLN).
Spirometry +ve Spirometry −ve
Lung monitor +ve 157 (46.6%) 6 (2.9%) 163
Lung monitor −ve 180 (53.4%) 201 (97.1%) 381
337 207 544
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systematically underestimated FEV6 values by −0.28 litres (Sup-
plementary Fig. 5).
Discriminatory accuracy of the post-bronchodilator lung moni-
tor was identical to that based on pre-bronchodilator data (C=
0.90; 95% CI 0.87, 0.92; Supplementary Fig. 6).
Sensitivity analyses: optimal cut-points for lung monitor FEV1/FEV6
ratio, relative to conﬁrmatory spirometry FEV1/FVC < LLN
In light of comparable test accuracy of the lung monitor based on
pre- and post-bronchodilator data, we explored optimal FEV1/FEV6
cut-points using pre-bronchodilator tests (Table 4).
Using an FEV1/FEV6 cut-point of <0.7 to deﬁne a positive test for
the lung monitor, sensitivity increased to 58.5% (95% CI 53.0, 63.8),
speciﬁcity was 98.6% (95% CI 95.8, 99.7) and the positive
predictive value increased to 72.0% (95% CI 57.4, 83.1) for a
population prevalence of 6% (Table 4). However, using a ﬁxed
ratio had little effect on the discriminatory accuracy of the lung
monitor (C= 0.91; 95% CI 0.89, 0.94; Supplementary Fig. 7).
In our sample, an FEV1/FEV6 cut-point of <0.78 had the best
overall test performance with sensitivity of 82.8% (95% CI 78.3%,
86.7) and speciﬁcity of 85.0% (95% CI 79.4%, 89.6%). Using this
cut-point would result in the lung monitor only missing 17.2% of
true positives and correctly identifying the majority of patients
without the disease. Furthermore, this cut-point would result in
57% of those screened requiring conﬁrmatory spirometry. The
positive predictive value for a population COPD prevalence of 6%
was estimated to be 26.1% (95% CI 25.0, 27.2) meaning that
around one in four patients referred for conﬁrmatory spirometry
would result in a diagnosis.
The above pattern was broadly similar when analyses were
repeated using the ﬁxed ratio to deﬁne obstruction for
conﬁrmatory spirometry (FEV1/FVC < 0.7), though sensitivity was
slightly lower at each cut-point and speciﬁcity remained at 100%
until FEV1/FEV6 > 0.7 (Supplementary Table 1). These analyses may
reﬂect the test performance when using the simpler criterion for
the lung monitor in countries deﬁning airﬂow obstruction as FEV1/
FVC < 0.7, such as the UK.28
DISCUSSION
We found that the lung monitor has high discriminatory accuracy
among patients with existing chronic respiratory symptoms. This
supports its suitability, either alone or perhaps in combination
with a symptom questionnaire, as a screening test prior to
conﬁrmatory spirometry. We further demonstrated that using a
bronchodilator with the lung monitor as part of screening offers
no performance advantage.
Importantly, the lung monitor demonstrated good test perfor-
mance despite being delivered with minimal coaching and only
requiring a maximum of three blows, rather than the possible six
blows to achieve repeatability with conﬁrmatory spirometry.
Using pre-bronchodilator FEV1/FEV6 < LLN, the lung monitor
missed half of COPD cases identiﬁed by FEV1/FVC < LLN from
conﬁrmatory spirometry but detected virtually all non-COPD cases
correctly. When using pre-bronchodilator FEV1/FEV6 < 0.70, the
lung monitor detected a higher proportion of true positives, the
same proportion of true negatives and the discriminatory accuracy
remained constant (C= 0.90 vs C= 0.91). Given the added
complexity of applying LLN to the lung monitor as it is not
connected to computer software, it appears justiﬁable to apply an
FEV1/FEV6 ﬁxed ratio to the lung monitor for purposes of
screening, while maintaining the LLN for diagnosing and
monitoring COPD.29–32
Test performance varied considerably depending on the
speciﬁed cut-point of the pre-bronchodilator FEV1/FEV6 ratio.
Our proposed optimal cut-point of <0.78 was similar to previous
studies, which had suggested using cut-points of <0.75,21 <0.7819
and <0.80.20 The sensitivity and speciﬁcity of the lung monitor in
our sample was acceptable for a screening test, missing <20% of
COPD cases, while 1 in 4 patients of the 57% referred for
conﬁrmatory spirometry were true positives and therefore would
be eligible for diagnosis and relevant treatment. While FEV1/FEV6
< 0.78 appeared the most efﬁcient in our sample, if the lung
monitor were to be used as a screening test the cut-point could be
modiﬁed according to the balance of acceptable false negative
rates and availability of resources.
We have assessed the screening test performance of one type
of microspirometer. One factor affecting accuracy may be the
Table 4. Screening accuracy of pre-bronchodilator lung monitor FEV1/FEV6 cut-points, against post-BD conﬁrmatory spirometry (FEV1/FVC < LLN).
TP FP TN FN Sens (95% CI) Spec (95% CI) PPV (3%
prevalence)
PPV (6%
prevalence)
PPV (10%
prevalence)
Proportion
referred to
diagnostic
testa
Proportion of
true cases
misseda
<0.4 6 0 207 331 1.79 (0.7, 3.8) 100 (98.2, 100) — — — 1.1% 98.2%
<0.5 34 0 207 303 10.1 (7.1, 13.8) 100 (98.2, 100) — — — 6.3% 89.9%
<0.6 88 1 206 249 26.1 (21.5, 31.1) 99.5 (97.3, 100) 0.63 (0.19, 0.92) 0.78 (0.33, 0.96) 0.86 (0.46, 0.98) 16.4% 73.9%
<0.7 197 3 204 140 58.5 (53.0, 63.8) 98.6 (95.8, 99.7) 0.56 (0.39, 0.70) 0.72 (0.57, 0.83) 0.82 (0.70, 0.90) 36.8% 41.5%
<0.71 207 4 203 130 61.4 (56.0, 66.6) 98.1 (95.1, 99.5) 0.50 (0.38, 0.61) 0.67 (0.56, 0.77) 0.78 (0.69, 0.85) 38.8% 38.6%
<0.72 220 7 200 117 65.3 (59.9, 70.4) 96.6 (93.2, 98.6) 0.37 (0.31, 0.44) 0.55 (0.48, 0.62) 0.68 (0.62, 0.74) 41.7% 34.7%
<0.73 234 9 198 103 69.4 (64.2, 74.3) 95.7 (91.9, 98.0) 0.33 (0.29, 0.38) 0.50 (0.45, 0.56) 0.64 (0.59, 0.69) 44.7% 30.6%
<0.74 244 12 195 93 72.4 (67.3, 77.1) 94.2 (90.1, 97.0) 0.28 (0.25, 0.31) 0.44 (0.41, 0.48) 0.58 (0.54, 0.62) 47.1% 27.6%
<0.75 253 17 190 84 75.1 (70.1, 79.6) 91.8 (87.2, 95.1) 0.22 (0.20, 0.24) 0.37 (0.34, 0.39) 0.50 (0.48, 0.53) 49.6% 24.9%
<0.76 264 25 182 73 78.3 (73.6, 82.6) 87.9 (82.7, 92.0) 0.17 (0.16, 0.18) 0.29 (0.28, 0.31) 0.42 (0.40, 0.44) 53.1% 21.7%
<0.77 273 29 178 64 81.0 (76.4, 85.1) 86.0 (80.5, 90.4) 0.15 (0.14, 0.16) 0.27 (0.26, 0.28) 0.39 (0.38, 0.41) 55.5% 19.0%
<0.78 279 31 176 58 82.8 (78.3, 86.7) 85.0 (79.4, 89.6) 0.15 (0.14, 0.15) 0.26 (0.25, 0.27) 0.38 (0.37, 0.39) 57.0% 17.2%
<0.79 287 41 166 50 85.2 (80.9, 88.8) 80.2 (74.1, 85.4) 0.12 (0.11, 0.12) 0.22 (0.21, 0.22) 0.32 (0.31, 0.33) 60.3% 14.8%
<0.8 295 48 159 42 87.5 (83.5, 90.9) 76.8 (70.5, 82.4) 0.10 (0.10, 0.11) 0.19 (0.19, 0.20) 0.30 (0.29, 0.30) 63.1% 12.5%
<0.9 333 182 25 4 98.8 (97.0, 99.7) 12.1 (8.0, 17.3) 0.03 (0.03, 0.03) 0.07 (0.07, 0.07) 0.11 (0.11, 0.11) 94.7% 1.2%
TP true positives, FP false positives, TN true negatives, FN false negatives, Sens sensitivity, Spec speciﬁcity, PPV positive predictive value
aAssuming 6% COPD prevalence
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different lung function indices being measured: FEV6 by the lung
monitor vs FVC by the ndd device (conﬁrmatory spirometry). We
assessed test performance of both devices using FEV1/FEV6 < LLN
as the cut-off for a positive result, relative to conﬁrmatory
spirometry FEV1/FVC < LLN. The ndd device had sensitivity of
80.4% and speciﬁcity of 98.1%, compared with the lung monitor
sensitivity of 50.5% and speciﬁcity of 99.0%. This suggests that the
difference in indices only partly affects performance. Another
important difference to consider is the type of sensor used in the
two devices for ﬂow/volume measurement (turbine in the lung
monitor vs ultrasonic in the ndd), as evidence suggests a degree
of inaccuracy in turbine devices.33,34
Our analysis sample had fewer controls than determined by our
sample size calculation, containing 207 instead of 248. While the
precision around speciﬁcity was reduced, the precision around
sensitivity estimates was unaffected; the latter being arguably
more important in the context of screening.
Using the LLN criteria to deﬁne cases in our primary analysis
ensured an accurate assessment of lung function, without added
‘noise’ from misdiagnosed patients which can be introduced when
using the FEV1/FVC < 0.7 ratio.
32 As the majority of previous
microspirometry test accuracy studies used the ﬁxed ratio
deﬁnition of obstruction,19–21,24,25,27,35 our study has made a
valuable contribution to the evidence base.
Owing to the case–control study being nested within a larger
COPD cohort study, the analysis sample had a higher prevalence
of COPD and possibly more advanced disease than would be
observed in an undiagnosed primary care population reporting
respiratory symptoms. Therefore, our study is at potential risk of
spectrum bias, as the reported sensitivities and speciﬁcities may
not fully reﬂect the test performance of the lung monitor if used
as a screening tool within symptomatic patients with lower
prevalence of COPD. However, by using Bayes’ Theorem the
reported post-test estimates were based on current UK COPD
prevalence of 3–10%, mitigating against this risk.
Nearly a third of our sample was a screened population,
suggesting that our ﬁndings will resonate with potential screening
processes, as patients could be selected for microspirometry on
the basis of symptom- or risk-based screening tests. Furthermore,
the fact that we included patients with chronic respiratory
symptoms and a range of lung function severities means that
our results may apply to an undiagnosed population with a similar
symptom proﬁle. In addition, our study was not restricted to ever-
smokers, unlike previous studies.14,19,21,22,25
For practical reasons, the same researcher administered both
the lung monitor and conﬁrmatory spirometry. Although research-
ers only recorded raw FEV1 and FEV6 lung monitor values and did
not calculate obstruction from this ﬁrst test, it is possible that
researchers were not entirely blind when administering the
conﬁrmatory spirometry to the patient. While this introduced a
risk of review bias, this was minimised as researchers received
standardised training to give only brief instruction for lung
monitor tests and proper coaching for conﬁrmatory spirometry.
Most previous studies have either used only pre-bronchodilator
microspirometry19–21,23–26 or post-bronchodilator microspirome-
try,27 and the only study to measure pre- and post-bronchodilator
microspirometry did not report comparative test accuracy.22 By
demonstrating the comparability of test performance irrespective
of bronchodilation, our study supports the continued use of pre-
bronchodilator microspirometers for screening purposes.
Participants performed three blows using the lung monitor,
irrespective of blow quality as indicated by the device’s in-built
quality alert, with the highest recorded readings being used for
analyses. While this follows some previous studies,23,25,26 had we
required all lung monitor blows to be technically valid19,20,22 we
may have obtained greater FEV1 or FEV6 values for some
participants. Furthermore, like most studies we did not assess
within-participant repeatability across blows on the lung monitor,
though this has been done in at least one study.21
The observed test performance of the lung monitor suggests
that it could be reliably used as a screening tool in patients
perceived to be at risk of COPD, to select those requiring
conﬁrmatory spirometry. The efﬁciency of the diagnostic spiro-
metry test could therefore be substantially increased, by patients
highly unlikely to have airﬂow obstruction being screened out in
advance. Screening at-risk symptomatic patients with a lung
monitor rather than referring all patients for conﬁrmatory
spirometry also represents ﬁnancial savings, with the handheld
device being approximately one tenth of the cost of diagnostic
spirometers. Resource savings could be realised in practices
irrespective of whether they conduct conﬁrmatory spirometry ‘in
house’ or refer patients to a lung function unit, as both models
would reduce the number of patients performing this
diagnostic test.
The ability to use a ﬁxed ratio for the lung monitor rather than
the LLN to assess airﬂow obstruction represents a time saving for
clinicians, who would otherwise need to use software to refer to
reference equations. The comparable test performance of the lung
monitor irrespective of bronchodilation supports the use of pre-
bronchodilator tests, further contributing to the efﬁciency and
ease of the screening test, a key consideration in the context of
time-pressured primary care consultations.
The lung monitor could potentially be administered by any
member of a primary care team, as it is a simple device requiring
minimal training. This would be beneﬁcial in general practice
where staff may be unfamiliar with the device19 and the simplicity
may minimise the risk of becoming de-skilled in using the lung
monitor, in contrast to conﬁrmatory spirometry where clinicians’
skills can reduce over time if they do not perform the test
regularly.36
The simplicity of the lung monitor, the minimal number of
required blows and its good test performance suggests that it
could be particularly useful as a screening test in patients with
poor coordination or lower cognitive ability. Furthermore, our
Patient Advisory Group preferred the lung monitor over other
microspirometer models suggesting that it may be more
acceptable to patients.
While we have suggested optimal cut-points based on the
balance of sensitivity and speciﬁcity, in practice, the optimal cut-
point would be determined by the clinical setting in which the
lung monitor was being used. For example, in settings where
access to quality conﬁrmatory spirometry may not be available,
particularly in low-resource settings, speciﬁcity of the lung
monitor may be prioritised. In these settings, using thresholds
with higher speciﬁcity could effectively exclude the majority of
those with respiratory symptoms who do not have COPD, thus
preventing overdiagnosis.
In addition to use as a screening tool, the accurate measure-
ment of FEV1 may indicate that the device could be used to
monitor obstruction severity or lung function decline among
diagnosed COPD patients, for example during annual reviews.
Further research would be needed to explore this, but the
potential time and cost savings afforded by using the lung
monitor instead of conﬁrmatory spirometry may be attractive to
General Practitioner practices, who would still obtain annual FEV1
values as recommended by bodies such as the National Institute
for Health and Care Excellence in the UK.28
Future research could build on preliminary evidence regarding
microspirometer screening strategies,13,14 which could be imple-
mented in differing clinical or economic contexts. Using a
combination of microspirometry and screening questionnaires
for example may prove more efﬁcient than microspirometry alone.
Furthermore, rather than using one cut-point to identify patients
requiring conﬁrmatory spirometry, certain contexts may warrant
using two cut-points to refer only those patients where there is
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uncertainty about their diagnosis. For example, in low- and
middle-income countries where availability of conﬁrmatory
spirometry may be limited, a three-tiered approach may be
plausible whereby the top proportion of patients are deﬁned test
negative, the bottom proportion are deﬁned as test positive and
the middle proportion are referred for conﬁrmatory spirometry.
Our results show that the Vitalograph lung monitor, which is a
cheap and simple device, has acceptable accuracy for use within a
screening pathway for undiagnosed COPD among primary care
patients with respiratory symptoms. We have established that the
test performance of the lung monitor is unaffected by broncho-
dilation, and our optimum cut-point of FEV1/FVC < 0.78 supports
previous studies, with no observed advantage of using LLN for this
screening test. Our paper makes a valuable contribution to the
evidence base concerning potential COPD screening tests, though
more work is required to inform the need for a formal screening
programme.
METHODS
Study design
We conducted a prospective case–control study to evaluate the screening
performance of the Vitalograph® lung monitor (Vitalograph Ltd, Bucking-
ham, UK), nested within a large COPD Cohort study.
Participant recruitment
Study participants were drawn from those attending for their 3-year
follow-up assessment as part of the Birmingham COPD Cohort Study,
which has been reported in detail elsewhere.37 In brief, participants were
primary care patients aged ≥40 years, who either had previously clinically
diagnosed COPD or had reported chronic respiratory symptoms as part of
a case-ﬁnding trial.38 Participants from the case-ﬁnding trial were invited to
join the Cohort study, irrespective of their spirometry results, if they
reported chronic cough or phlegm for ≥3 months for at least 2 years,
wheeze in the past 12 months or dyspnoea of MRC grade ≥2.
At the 3-year follow-up assessment visit, cohort participants were invited
to take part in the additional tests for this case–control study (Fig. 2) and
those who agreed were asked to sign a consent form. Those who declined
to participate completed the standard Cohort assessment. The National
Research Ethics Service Committee West Midlands, Solihull provided
approval for both the Birmingham COPD Cohort (11/WM/0304) and the
case-ﬁnding trial (11/WM/0403).
Data collection and clinical measures
In addition to the lung function tests described below, participants
underwent the standard Cohort follow-up assessment, which included
various physiological and anthropometric measurements (height, weight,
grip strength, exercise capacity) as well as completing questionnaires.
Index test: lung monitor microspirometry
Participants received pre- and post-bronchodilator microspirometry with
the Vitalograph lung monitor prior to conﬁrmatory post-bronchodilator
spirometry (Fig. 1). The lung monitor measured FEV1 and FEV6 in litres. In
contrast to conﬁrmatory spirometry, participants received minimal
explanation or coaching when using the lung monitor. Researchers told
participants to take a deep breath until lungs were full and blow into the
mouthpiece as hard and fast as they could until being told to stop.
Researchers demonstrated the correct technique once and then allowed
the participant to perform the blows themselves, without additional
coaching or encouragement. Participants performed three blows pre-
bronchodilator and three blows post-bronchodilator. Technically unsatis-
factory blows identiﬁed by the in-built quality assessment were recorded
on the case report form, but participants were not asked to repeat the
blow. The best FEV1 and FEV6 blows were used for analyses, irrespective of
quality and which blow attempt they came from.
Positive test results were deﬁned as being below the 5th percentile of
the predicted pre-bronchodilator FEV1/FEV6 ratio (i.e. the LLN) using the
NHANES III equations.39 Alternative positive test results were also pre-
speciﬁed, including post-bronchodilator FEV1/FEV6 below the LLN, and
various cut-points of the FEV1/FEV6 ratio.
Reference test: post-bronchodilator conﬁrmatory spirometry
Post-bronchodilator conﬁrmatory spirometry was conducted according to
American Thoracic Society and European Respiratory Society 2005
guidelines40 by trained researchers using the ndd Easy on-PC spirometer.
Participants received 400 μg of Salbutamol and after waiting at least
20min, performed a minimum of 3 (maximum of 6) blows until
repeatability was achieved. Although the lung monitor and spirometry
tests were administered by the same researcher, the tests were in effect
administered blind of each other, as researchers did not record the FEV1/
FEV6 ratio for the lung monitor before administering conﬁrmatory
spirometry.
Cases were deﬁned as participants whose predicted FEV1/FVC ratio was
below the LLN using the NHANES III equations, according to conﬁrmatory
spirometry. Participants not meeting this criterion formed the controls.
Aims
The primary aim was to assess the pre-bronchodilator test accuracy
(sensitivity and speciﬁcity) of the lung monitor (FEV1/FEV6) against post-
bronchodilator conﬁrmatory spirometry (FEV1/FVC), using the LLN deﬁni-
tion of airﬂow obstruction.
We also aimed to assess the correlation and agreement between lung
function measures from both devices and to compare test accuracy of pre-
Cohort study participants
40+ years, chronic respiratory
symptoms
Pre-bronchodilator
lung monitor
Performed by patient
with minimal instruction
from researcher
N=248 COPD +ve
N=248 COPD -ve
Post-bronchodilator
lung monitor
Performed by patient
with minimal instruction
from researcher
Post-bronchodilator
confirmatory spirometry
using ndd Easy on-PC
Instruction by intensively-
trained researcher
Primary outcome: assess sensitivity and specificity
of lung monitor compared to post-bronchodilator
confirmatory spirometry
Secondary outcome: comparison of test
performance using pre- vs post-
bronchodilator lung monitor
Patient assessment
Fig. 2 Case–control study design.
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and post-bronchodilator lung monitor data. Finally, to identify the
threshold that optimised sensitivity and speciﬁcity, we explored the effect
of using different FEV1/FEV6 thresholds, including the ﬁxed ratio of <0.7, to
deﬁne a positive test result on the lung monitor.
Sample size
We calculated that we required a sample size of 248 cases and 248 controls
to detect an assumed sensitivity of 85%21,27 while ensuring the lower
bound of the CI was >80%.
Statistical analysis
We evaluated the diagnostic test accuracy of the lung monitor (index test)
for all participants with complete data for the index and reference tests.
We estimated sensitivity and speciﬁcity of the lung monitor using pre-
bronchodilator data. We compared test accuracy of pre- and post-
bronchodilator lung monitor blows, using McNemar’s test. Using
continuous test values, we assessed the discriminatory accuracy of FEV1
and FEV6 measured by the lung monitor via receiver operating
characteristic curve analysis. We then conducted sensitivity analyses using
a ﬁxed ratio deﬁnition of obstruction to identify a lung monitor FEV1/FEV6
optimal threshold.
To account for the case–control study design, post-test probabilities
(herein referred to as positive predictive values (PPV)) were calculated
using Bayes’ Theorem to reﬂect current COPD prevalence in the UK. For our
tables and appendices, we calculated PPVs based on COPD prevalence
among adults aged ≥40 years being 3–10%.1,41
All analyses were conducted in Stata SE v15.
The paper was written according to the STARD guidance42 for reporting
studies of diagnostic accuracy.
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